Bill & Melinda Gates Foundation

Likarda is a biotech company focused on advancing cell therapies through innovative delivery technologies. Its proprietary Core-Shell Spherification® platform utilizes biocompatible hydrogel materials, such as Hyaluronic Acid and PEG, to create customizable microcapsules that house cell-based therapies. This platform addresses the unique requirements of various cell therapies, enabling applications in the treatment of diabetes, osteoarthritis, and joint pain. For diabetes, Likarda is developing methods to deliver islet-like cells, which have shown promising results in pre-clinical testing with animal models. In the case of osteoarthritis, encapsulated stem cells are designed for injection into the knee, providing a slow-release treatment that alleviates joint pain and promotes healing over several weeks. Likarda's versatility allows for both durable and degradable formulations, enhancing the efficacy of cell-based treatments. The company has gained recognition for its innovation, having been named one of the "50 Most Promising Start-Ups in the World" during Global Entrepreneurship Week, and has secured over $8 million in funding through various sources.

Leinco Technologies is a company that specializes in the development of high-purity monoclonal antibodies, proteins, and various reagents specifically for the diagnostic and biopharmaceutical industries. They provide a range of services, including in vitro antibody and protein production, antibody conjugations, and cell banking. Leinco Technologies focuses on augmenting the early discovery process in life science research and diagnostics, as well as contributing to the innovative development of protein therapeutics. Their expertise in optimizing and adapting products enables clients to effectively meet their research and development needs.

ReciBioPharm operates as a biologics company. ReciBioPharm is a division of Recipharm.

Aptitude Medical Systems is a biotechnology research company specializing in molecular recognition technology that utilizes aptamers to address the limitations of traditional antibodies. By developing highly stable and resistant aptamers, the company offers solutions that bind with high affinity and specificity to challenging targets, even discriminating between targets that differ by a single functional group. This innovation enables a range of applications across life sciences, diagnostics, and therapeutics, facilitating the creation of advanced products tailored to meet the stringent demands of molecular recognition. Through its partnerships, Aptitude aims to advance the capabilities of molecular diagnostics and therapeutic interventions.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Dyadic International is a biotechnology company based in Jupiter, Florida, with a research and development center in the Netherlands. The company focuses on the discovery, development, manufacture, and sale of enzymes and proteins for various industries, including bioenergy, bio-based chemicals, and biopharmaceuticals. Dyadic's core technology is its patented C1 fungus, which enables the efficient production of industrial enzymes and proteins at scale. This platform allows for the discovery of novel genes and proteins and has been licensed to several third parties, including Abengoa Bioenergy, BASF, and Codexis, for non-pharmaceutical applications. Dyadic seeks to maximize the value of its technologies through licensing arrangements and collaborations, providing partners with the ability to manufacture and utilize the enzymes produced through its innovative processes.

Freya Biosciences is a clinical-stage women's health company headquartered in Copenhagen and Boston, specializing in the development of microbial immunotherapies. The company focuses on addressing significant unmet medical needs across various indications by utilizing a proprietary platform to engineer and manufacture live microbes. These engineered microbes are designed to be both safe and effective for human use, facilitating the creation of innovative treatments for a range of diseases.

PopVax is a biotechnology company that developing novel mRNA vaccines and therapeutics using computational protein design.

CanSino Biologics focuses on the R&D, manufacturing, and commercialization of vaccine products for human use. These vaccine products include pneumococcal polysaccharide and conjugate vaccines, and a DTcP-based combo, and other items. It is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine.

Eyam Vaccines and Immunotherapeutics is a life science and medical research company focused on the development of vaccines to combat infectious diseases. The company specializes in researching vaccines that target the spike glycoprotein, which is crucial for generating neutralizing antibodies against pathogens such as the novel coronavirus. Eyam employs a self-amplifying vaccine platform that enables the design of low-dose vaccines with advanced targeting capabilities, ensuring comprehensive protection, including against emerging variants. Through its innovative approach, the company aims to address pressing healthcare challenges and enhance public health outcomes.

Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, that focuses on developing innovative CRISPR technology for the treatment of microbial diseases. Incorporated in 2017, the company aims to revolutionize healthcare by utilizing a programmable approach to the adaptive immune system, enabling the targeted elimination of hazardous bacteria based on their specific DNA sequences. Snipr Biome's novel medicines are designed to provide health professionals with effective tools for microbiome engineering, allowing for selective targeting and destruction of harmful bacteria in vivo.

Ethris GmbH is a biotechnology company based in Planegg, Germany, specializing in the development of innovative therapeutic solutions for diseases with unmet medical needs. The company has a focus on transcript therapeutics, particularly through its SNIM RNA platform, which offers a novel approach to treating various conditions by enabling the production of therapeutic proteins within the patient’s body. This platform presents an alternative to traditional recombinant protein and gene therapies, addressing a range of diseases, including rare and genetically predetermined conditions. Ethris also develops Magnetovax, a personalized tumor vaccine platform that utilizes magnetic fields for localized activation in tumors. The company has established strategic research collaborations with major pharmaceutical firms, enhancing its capabilities in regenerative medicine and therapeutic development. Founded in 2009, Ethris continues to advance its technologies to meet diverse medical needs.

Nanite is a biotechnology company focused on non-viral gene delivery through the development of programmable polymer nanoparticles. Utilizing an artificial intelligence-driven platform, Nanite integrates advanced high-throughput experimental and computational techniques to create tailored delivery vehicles capable of transporting a diverse array of genetic materials with specific targeting capabilities. This innovative approach aims to assist scientists in functional chemistry by providing therapeutically relevant solutions for gene delivery, enhancing the potential for various medical applications and indications.

Surf Bio is a preclinical biopharmaceutical company focused on developing innovative therapeutic solutions through its next-generation surfactant technology. This novel biotechnology platform aims to enhance drug effectiveness across various therapeutic areas, including diabetes, oncology, infectious diseases, and gene therapy. By utilizing this advanced technology, Surf Bio seeks to provide healthcare organizations worldwide with access to improved drugs that can better address the needs of patients suffering from critical diseases.

Owlstone Medical, established in 2003 and headquartered in Cambridge, UK, specializes in developing and commercializing breathalyzers for clinical diagnostics and precision medicine. The company's core technology, FAIMS, enables the detection of volatile organic compounds in breath, facilitating the discovery of non-invasive biomarkers for various diseases. Owlstone Medical's product portfolio includes breath samplers like ReCIVA and CASPER, as well as analytical tools such as Lonestar and ATLAS, catering to applications like lung cancer, asthma, and gastrointestinal disorders. The company collaborates with market leaders to integrate its technology into next-generation chemical sensing products and has received funding from the UK's Department of Defense to develop a handheld device for enhanced sensitivity and selectivity. Owlstone Medical aims to become a global leader in non-invasive diagnostics, with a focus on early disease detection and a pipeline of medical applications, including colon and lung cancer screening.

Owlstone Medical, established in 2003 and headquartered in Cambridge, UK, specializes in developing and commercializing breathalyzers for clinical diagnostics and precision medicine. The company's core technology, FAIMS, enables the detection of volatile organic compounds in breath, facilitating the discovery of non-invasive biomarkers for various diseases. Owlstone Medical's product portfolio includes breath samplers like ReCIVA and CASPER, as well as analytical tools such as Lonestar and ATLAS, catering to applications like lung cancer, asthma, and gastrointestinal disorders. The company collaborates with market leaders to integrate its technology into next-generation chemical sensing products and has received funding from the UK's Department of Defense to develop a handheld device for enhanced sensitivity and selectivity. Owlstone Medical aims to become a global leader in non-invasive diagnostics, with a focus on early disease detection and a pipeline of medical applications, including colon and lung cancer screening.

Sibel Health, established in 2018 and headquartered in Evanston, Illinois, specializes in advanced monitoring solutions for healthcare. The company develops soft, flexible sensors that provide clinical-grade, wireless vital signs monitoring, including heart rate, respiratory rate, skin temperature, body position, and activities. These sensors are designed for use on patients and pregnant mothers, offering a comprehensive physiological monitoring platform with advanced analytics for both clinical care and research applications. Sibel Health's innovative digital health solutions are tailored for the pharmaceutical and clinical research sectors, enhancing healthcare delivery and patient outcomes.

Corner Therapeutics is a biotechnology research company focused on advancing immunotherapy solutions. The company specializes in stimulating exceptional memory T cells to achieve lifelong immunity. It has developed a versatile dendritic cell hyperactivation (hDC) platform that induces strong T-cell responses, aiming to deliver robust and durable immunity against a wide array of cancers and infectious diseases. By providing these innovative technologies, Corner Therapeutics enables healthcare providers to enhance immune responses and promote long-lasting immunity, positioning itself at the forefront of immunotherapy research.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Phase Genomics is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing technology for ProxiMeta Hi-C genome assembly and metagenome deconvolution. Phase Genomics' platform aims to facilitate transformative discoveries in agriculture, human health, and industrial biology by providing scientists with highly accurate and detailed genomes and metagenomes. This enables researchers to make significant breakthroughs across various fields.

PhaSER Biomedical is Exploiting the 8HUM mouse, a unique mouse model with multiple utilities in drug discovery, and development.

ProteinLogic’s ImmiPrint® technology impacts the emerging market for diagnostic, predictive, prognostic and other biomarker applications.

C16 Biosciences, Inc. is a biotechnology company based in New York that specializes in producing sustainable alternatives to palm oil through microbial fermentation. Founded in 2017, the company employs its innovative biomanufacturing platform to create scalable and environmentally friendly ingredients for food manufacturers, refiners, and consumers. C16 Biosciences has developed the Palmless™ platform, which features its first biodesigned ingredient, Torula oil, known for its premium bioactive properties that support skin and hair health. By focusing on sustainable solutions, C16 Biosciences aims to help solidify supply chains for consumer product manufacturers while addressing the environmental challenges associated with traditional palm oil production.

Sail Biomedicines is a biotechnology company developing innovative medicines using circular RNA technology and programmable nanoparticles. Its platform, Endless RNA (eRNA), combined with unique, naturally-derived nanoparticles, enables the comprehensive programming of drugs, enhancing their potency and targeting capabilities. The company aims to transform patient care by leveraging artificial intelligence and advanced delivery systems to create first-in-class therapeutics.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Brightseed, Inc. is a pioneering biosciences company based in San Francisco, California, founded in 2017. It specializes in the discovery of bioactive compounds in plants that have beneficial effects on human health, particularly for chronic disease management. Utilizing its proprietary Forager platform, which incorporates artificial intelligence and machine learning, Brightseed accelerates the identification and validation of these naturally occurring compounds, transforming what was once a lengthy process into a matter of months. By mapping bioactives to specific health outcomes, Brightseed provides valuable insights and science-backed solutions to partners across the consumer health continuum. The company's innovative approach aims to illuminate the connections between nature and human health, ultimately improving quality of life and addressing health challenges through the exploration of previously uncharted plant compounds.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Molecular Loop is a biotechnology company focused on DNA sequencing. The company offers a unique approach to sequencing through its Molecular Loop targeting technology, which eliminates the need for a separate library preparation process. This innovation allows for amplicons designed to overlap extensively across target strands, providing sequence data without the added complexity and costs associated with traditional shotgun library methods. Additionally, Molecular Loop provides custom assays based on user-provided content, along with expanded and customizable carrier screening panels and research panels for SARS-CoV-2. These offerings enable healthcare professionals and researchers to access efficient systems for production-scale targeted sequencing applications.

Naobios is a contract development and manufacturing organization (CDMO) located in Saint Herblain, France. The company specializes in bioprocess development and offers good manufacturing practice (GMP) production services for clinical batches of various biological products, including viral vaccines, oncolytic viruses, viral vectors, and challenge agents. With expertise in optimizing production processes, Naobios supports the development of live vaccine products, contributing to advancements in biopharmaceutical manufacturing.

BiomEdit is an innovation company focused on developing novel probiotics, microbiome-derived bioactives, and engineered microbial medicines to meet unmet needs in animal health. The company aims to address significant challenges in animal agriculture and food security by harnessing the potential of the microbiome. BiomEdit employs a unique platform that combines high-throughput sequencing and data analytics to efficiently discover and screen new probiotic species and bioactive molecules. These innovations can be engineered for enhanced stability and improved production of beneficial metabolites or immune-modulating proteins. The resulting probiotics and microbially-derived compounds represent advanced solutions designed to promote animal health while minimizing reliance on antibiotics.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

STRM.BIO is a biotechnology company focused on advancing gene therapy through the innovative use of extracellular vesicles (EVs). By leveraging the natural properties of EVs, which can efficiently deliver nucleic acids and proteins, the company aims to establish a new class of therapeutics that enhance the effectiveness of existing treatments while simplifying the delivery process. STRM.BIO emphasizes safety and practicality in its approach, utilizing EVs as low-immunogenic carriers that can be mass-produced for commercial use. The company's mission is to fulfill the potential of gene therapy by providing patients with more effective and accessible treatment options.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Aptitude Medical Systems is a biotechnology research company specializing in molecular recognition technology that utilizes aptamers to address the limitations of traditional antibodies. By developing highly stable and resistant aptamers, the company offers solutions that bind with high affinity and specificity to challenging targets, even discriminating between targets that differ by a single functional group. This innovation enables a range of applications across life sciences, diagnostics, and therapeutics, facilitating the creation of advanced products tailored to meet the stringent demands of molecular recognition. Through its partnerships, Aptitude aims to advance the capabilities of molecular diagnostics and therapeutic interventions.

Co-Diagnostics, Inc. is a molecular diagnostics company based in Salt Lake City, Utah, founded in 2013. The company specializes in the development, manufacture, and marketing of advanced diagnostic technologies that focus on the detection and analysis of nucleic acid molecules, such as DNA and RNA. In addition to creating reagents for diagnostic tests, Co-Diagnostics offers self-contained lab systems that incorporate diagnostic equipment from other manufacturers. The company also leverages its proprietary technology to design targeted tests for identifying genetic markers, which can be utilized in various industries beyond infectious diseases, while licensing these tests to specific customers.

Aphea.Bio is a company focused on developing next-generation biopesticides and biostimulants derived from natural microorganisms. Its biopesticides serve as an alternative to conventional chemical pesticides, addressing the increasing pressure on synthetic chemical use in agriculture. Additionally, the company creates biostimulants that enhance crop growth by improving the uptake of nutrients from the soil. Aphea.Bio's products aim to sustainably increase crop yields and health, specifically targeting crops such as maize and wheat. By utilizing proprietary technologies, the company accelerates the discovery of innovative biocontrol and biostimulant solutions, enabling farmers to manage pests, diseases, and fertilizer application more effectively.

Latham BioPharm Group is a firm specializing in life sciences, offering comprehensive expertise in business development, program management, quality assurance, regulatory affairs, and strategic consulting. With a team that boasts an average of over 20 years of experience, including roles as senior executives in both startups and Fortune 200 companies, Latham BioPharm has a strong foundation in guiding clients through the complexities of product development. The company has a proven track record in biodefense and pandemic response, having successfully assisted clients in identifying and securing funding, managing programs, and monetizing opportunities across various sectors. Their services include strategy and portfolio analysis, market research, and connecting clients with target markets to enhance decision-making. Latham BioPharm's expertise has contributed to generating substantial government funding and licensing fees, positioning them as a key partner in advancing innovations in vaccines, therapeutics, medical devices, and diagnostics.

Aegis Life is a biotechnology company focused on advancing nucleic acid delivery technology, specifically through its proprietary platform known as fusogenix PLV. With over two decades of dedicated research and development, the company aims to facilitate the discovery, clinical development, and manufacturing of vaccines and therapeutics targeting infectious diseases. Aegis Life's innovative technology enables the rapid development of solutions to combat a range of health threats, including COVID-19 and other emerging contagions. Through its efforts, the company supports the pharmaceutical industry in addressing urgent public health challenges effectively.

The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Smart Immune is a clinical-stage biotechnology company dedicated to advancing hematopoietic stem cell-based biotherapies aimed at improving the prognosis and quality of life for patients with severe diseases. The company's primary focus is on its innovative cell therapy program that utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This program is complemented by integrative developments in targeted conditioning, gene therapy, and genome editing, allowing for the creation of next-generation treatments. Smart Immune's approach aims to provide effective allogeneic T-cell therapies for patients suffering from life-threatening conditions, particularly hematological malignancies and primary immune deficiencies.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

SpyBiotech Limited is a biotechnology company based in Oxford, United Kingdom, founded in 2017. The company specializes in the development of molecular superglue technology, which is utilized to create next-generation vaccines. This proprietary platform allows for the bonding of antigens to viruses and other particles, facilitating the rapid development of vaccines targeting a variety of diseases. By employing this innovative approach, SpyBiotech aims to enhance vaccine efficacy and reduce the time required for development, thereby providing medical institutions and research centers with advanced solutions for combating bacterial infections and other health challenges.

UW Medicine is a clinical research and healthcare system that provides a higher degree of healthcare for pre-med students. UW Medicine health professionals provide the most up-to-date care for each individual patient through these integrated programs, lead one of the world's largest and most comprehensive medical research programs, and provide innovative learning programs for students, trainees, and practitioners in the health professions. UW Medicine, as the region's only comprehensive clinical, research, and learning health system, provides a higher level of healthcare, ranging from primary and preventive care to the most highly specialized care for the most complex medical conditions.

LumiraDx Ltd, incorporated in 2016 and based in London, United Kingdom, is a next-generation point-of-care diagnostics company. It specializes in manufacturing an innovative diagnostic platform that provides a wide range of tests with lab-comparable performance. LumiraDx aims to transform healthcare by offering solutions that facilitate integrated, patient-centered care, enhancing safety, efficiency, and health outcomes. The company's diagnostic system includes a portable instrument, low-cost test strips, and seamless digital connectivity, making diagnostic-led care simpler and more accessible. LumiraDx operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated from the U.S. market.

ExploRNA Therapeutics is focused on advancing messenger ribonucleic acid (mRNA) as a therapeutic platform for anti-cancer applications and vaccinations. The company develops innovative therapeutics by modifying the cap structure of mRNA, which enhances its stability and translation efficiency. This technology enables the medical community to stimulate adaptive immune responses, ultimately aiming to improve treatment outcomes for patients. ExploRNA Therapeutics collaborates with pharmaceutical partners to implement its ideas into distinct therapeutic programs, providing both technology and medications that address critical health challenges. Through its cutting-edge research and development efforts, the company is positioned to make significant contributions to the field of mRNA therapeutics.

Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, specializing in DNA therapies and technology. Founded in 2007, the company has developed the proTL synthetic DNA platform, which enables the production of closed linear DNA, known as doggybone DNA, without the need for bacterial fermentation. This innovative platform is designed for various applications, including veterinary vaccines, monoclonal antibodies, cancer and gene therapies, allergy treatments, RNA interference therapies, and stem cell reprogramming. Touchlight Genetics is led by a team with significant expertise in life sciences, including founder and CEO Jonny Ohlson and Non-Executive Chairman Clive Dix. The company has successfully established collaborations with prominent academic institutions such as Imperial College London and the University of Pennsylvania, enhancing its research capabilities and expanding its impact in the field of DNA vaccine development for oncology and infectious diseases.

Adapsyn Bioscience, founded in 2016 and based in Hamilton, Canada, is a biotechnology company focused on discovering and developing novel medicines derived from organic biomolecules. The company's primary product is the Adapsyn platform, which utilizes proprietary algorithms and artificial intelligence to analyze genomic and metabolomic data from microbes. This platform includes several key components: PRISM for identifying natural product biosynthetic gene clusters in microbial genomes; GARLIC for defining gene clusters that encode natural product drug variants and novel candidates; GRAPE for revealing evolved drug fragments from known products; and CLAMS for matching gene clusters to mass spectrometry peaks/compounds from complex mixtures. Adapsyn Bioscience leverages these advanced bioinformatic tools and state-of-the-art laboratory facilities to support researchers in identifying a diverse range of drugs, ultimately accelerating the discovery of medicines to combat various diseases.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

Eleven Therapeutics is a biotechnology company leveraging artificial intelligence to advance medicinal nucleic acids, particularly focusing on RNAi therapies and mRNA therapeutics. The company employs AI-driven parallel functional testing and combinatorial chemistry to develop programmable molecules called SCSI-RNAs, which can target specific diseases or biological targets. Additionally, Eleven Therapeutics is pioneering extended durability mRNA therapeutics designed to address unmet medical needs in metabolic, endocrinologic, and infectious diseases. Their proprietary high-throughput AI-enabled screening platforms enhance the stability and targeted delivery of these nucleic acid molecules, ensuring superior durability and specificity.

Enko Chem, Inc., established in 2017 and based in Woburn, Massachusetts, specializes in the discovery and development of small-molecule and novel products designed to protect crops from pests and diseases. The company's proprietary technology platform enables it to swiftly identify safe and cost-effective solutions, contributing to sustainable food production.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

Flywheel.io is a cloud-based data management platform tailored for biomedical research and collaboration. Founded in 2012 and headquartered in Minneapolis, Minnesota, the company provides a suite of tools designed to enhance the workflow of scientists and researchers. Its platform supports medical imaging, scientific computation, and content management, enabling users to capture, manage, and analyze research data efficiently. By utilizing cloud scalability and automation, Flywheel facilitates collaborative research, machine learning applications, and multicenter studies, which help organizations streamline their research processes. The platform, featuring a modern web interface and extensible compute engine, aims to eliminate bottlenecks in innovation, allowing researchers to focus on scientific discovery rather than IT challenges.

Phase Genomics is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing technology for ProxiMeta Hi-C genome assembly and metagenome deconvolution. Phase Genomics' platform aims to facilitate transformative discoveries in agriculture, human health, and industrial biology by providing scientists with highly accurate and detailed genomes and metagenomes. This enables researchers to make significant breakthroughs across various fields.

Cardea Bio, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing bioelectronics for research and diagnostics. Established in 2013, Cardea utilizes proprietary graphene-based digital biosensors to create advanced biosensor hardware, software, and molecular infrastructure, enabling precision healthcare through improved diagnostic capabilities. The company's product offerings include the AGILE R100, an innovative assay for drug discovery, and the AGILE R200, an automated high-throughput screening solution. Cardea's biosensors convert biomolecular interactions into digital data, allowing for real-time biological signal analysis and access to streaming multi-omics data. Their solutions cater to various applications in life sciences and healthcare, such as small molecule validation, antibody characterization, and biomolecular analysis.

Yemaachi Biotechnology is a company focused on advancing cancer diagnosis and treatment through innovative technology. Utilizing immunogenomics, bioinformatics, and artificial intelligence, Yemaachi aims to enhance the development of effective strategies for cancer detection and treatment. The company's platform is designed to improve patient outcomes and reduce the economic burden associated with cancer care. By combining these advanced technologies, Yemaachi seeks to provide more effective therapeutic solutions for cancer patients.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Providence Therapeutics Inc. is a biotechnology company based in Toronto, Canada, founded in 2015. The company specializes in the development and manufacture of messenger ribonucleic acid (mRNA) vaccines formulated in lipid nanoparticles. Providence Therapeutics focuses on personalized cancer therapies, notably creating mRNA vaccines that target specific tumor mutations to elicit an immune response against cancer cells, particularly for advanced ovarian cancer. In addition to its oncology initiatives, the company has developed vaccines for other diseases, including PTX-101 for cancer and PTX-COVID19-B and PTX-COVID19-T for COVID-19. Providence Therapeutics aims to address unmet medical needs by providing safe and effective vaccines and therapies to improve patient outcomes.

Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.

Brightseed, Inc. is a pioneering biosciences company based in San Francisco, California, founded in 2017. It specializes in the discovery of bioactive compounds in plants that have beneficial effects on human health, particularly for chronic disease management. Utilizing its proprietary Forager platform, which incorporates artificial intelligence and machine learning, Brightseed accelerates the identification and validation of these naturally occurring compounds, transforming what was once a lengthy process into a matter of months. By mapping bioactives to specific health outcomes, Brightseed provides valuable insights and science-backed solutions to partners across the consumer health continuum. The company's innovative approach aims to illuminate the connections between nature and human health, ultimately improving quality of life and addressing health challenges through the exploration of previously uncharted plant compounds.

Reithera Srl is a company devoted to develop and produce biopharmaceutical products based on gene delivery technologies for advanced therapies, in order to prevent and treat several serious or life-threatening diseases.

Eleven Therapeutics is a biotechnology company leveraging artificial intelligence to advance medicinal nucleic acids, particularly focusing on RNAi therapies and mRNA therapeutics. The company employs AI-driven parallel functional testing and combinatorial chemistry to develop programmable molecules called SCSI-RNAs, which can target specific diseases or biological targets. Additionally, Eleven Therapeutics is pioneering extended durability mRNA therapeutics designed to address unmet medical needs in metabolic, endocrinologic, and infectious diseases. Their proprietary high-throughput AI-enabled screening platforms enhance the stability and targeted delivery of these nucleic acid molecules, ensuring superior durability and specificity.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines utilizing its proprietary virus-like particle (VLP) platform technology. This innovative approach allows for the multivalent, particle-based display of complex viral antigens, which is aimed at generating broad and durable immune responses. Icosavax focuses primarily on life-threatening respiratory diseases, with its lead vaccine candidate, IVX-121, targeting respiratory syncytial virus (RSV) in older adults. The company's pipeline also includes candidates for human metapneumovirus (hMPV) and SARS-CoV-2, reflecting its commitment to advancing vaccine solutions for infectious diseases.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Enko Chem, Inc., established in 2017 and based in Woburn, Massachusetts, specializes in the discovery and development of small-molecule and novel products designed to protect crops from pests and diseases. The company's proprietary technology platform enables it to swiftly identify safe and cost-effective solutions, contributing to sustainable food production.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with an additional office in Conshohocken. Founded in 1999, the company focuses on the discovery and development of innovative T cell receptor-based therapeutics aimed at addressing significant unmet medical needs in cancer, viral diseases, and autoimmune diseases. Immunocore specializes in engineering T cell receptors (TCRs) and linking them to antibody fragments, which has led to the development of its lead product candidate, IMCgp100, currently undergoing clinical trials for metastatic melanoma. The company's proprietary TCR technology platform is validated and designed for efficient manufacturing, supporting both clinical and commercial supply. Immunocore was previously known as Avidex Limited before adopting its current name in 2008.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, that specializes in developing a proprietary technology platform for the direct and selective capture of large necrotic particles from physiological solutions such as whole blood, serum, and plasma. This platform facilitates the detection of diseases, particularly cancers, in their earliest stages by enabling access to native-state biomarkers and nanoparticles for multiomics applications. The company offers various products and services, including the TR(ACE) Assay for monitoring treatment responses in cancer, tissue-based molecular and cfDNA liquid biopsy testing for personalized medicine, and a biomarkers program aimed at drug development for Alzheimer's disease. Additionally, Biological Dynamics provides clinical laboratory services, including molecular and next-generation sequencing, and supports applications in autoimmune diseases, transplant rejection, and traumatic brain injury. Founded in 2008, the company is dedicated to improving global health outcomes through innovative diagnostic solutions.

Landcent is a company dedicated to combating global infectious diseases, with a focus on malaria. It develops and delivers affordable, sustainable solutions that are safe for large-scale use, aiming to accelerate the fight against these diseases and ultimately eliminate them.

RJH Biosciences is a biotechnology company dedicated to the development of transfection reagents and delivery agents for nucleic acids. It focuses on creating innovative systems that effectively transport various types of nucleic acids to human cells and cell lines, particularly targeting blood cancers and the modification of immune cells. By advancing these technologies, RJH Biosciences aims to enable healthcare professionals to harness the therapeutic potential of nucleic acids, ultimately contributing to the development of new medical treatments. The company distributes its products through its website and engages in projects that further enhance its offerings in the field of biotechnology.

One.bio is an emerging biotechnology company spun out from UC Davis, specializing in the development of naturally-derived oligosaccharides for food, agriculture, and biopharmaceutical applications. Utilizing proprietary technology, the company creates novel oligosaccharides from natural products aimed at positively influencing the microbiome and enhancing immune function. One.bio's innovative ingredients provide clients with access to prebiotics and therapies that support both human and animal health, positioning the company as a significant player in the fields of nutrition and longevity.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, that specializes in developing a proprietary technology platform for the direct and selective capture of large necrotic particles from physiological solutions such as whole blood, serum, and plasma. This platform facilitates the detection of diseases, particularly cancers, in their earliest stages by enabling access to native-state biomarkers and nanoparticles for multiomics applications. The company offers various products and services, including the TR(ACE) Assay for monitoring treatment responses in cancer, tissue-based molecular and cfDNA liquid biopsy testing for personalized medicine, and a biomarkers program aimed at drug development for Alzheimer's disease. Additionally, Biological Dynamics provides clinical laboratory services, including molecular and next-generation sequencing, and supports applications in autoimmune diseases, transplant rejection, and traumatic brain injury. Founded in 2008, the company is dedicated to improving global health outcomes through innovative diagnostic solutions.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

AbCellera is a biotechnology company specializing in antibody discovery and development. It uses an integrated platform combining proprietary hardware, software, tools, and advanced data science to efficiently identify and develop optimal antibodies for clinical use. The company partners with both emerging biotechs and established pharmaceutical companies, leveraging its expertise to accelerate the drug development process and improve patient outcomes.

Phase Genomics is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing technology for ProxiMeta Hi-C genome assembly and metagenome deconvolution. Phase Genomics' platform aims to facilitate transformative discoveries in agriculture, human health, and industrial biology by providing scientists with highly accurate and detailed genomes and metagenomes. This enables researchers to make significant breakthroughs across various fields.

Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Lyell Immunopharma Inc is a clinical-stage cell therapy company focused on developing innovative treatments for patients with solid tumors through T cell reprogramming. The company aims to overcome significant challenges in adoptive T cell therapy, specifically T cell exhaustion and loss of durable stemness, which impede effective and lasting responses in cancer treatment. Utilizing its proprietary platforms, Gen-R and Epi-R, Lyell is working to enhance the proliferative capacity, self-renewal, and differentiation abilities of T cells. The company's product pipeline includes several candidates, such as LYL797, LYL119, and LYL845, all designed to deliver improved and potentially curative outcomes for patients suffering from solid tumors.

Evolve Biosystems, Inc. is a life sciences company based in Davis, California, that focuses on developing probiotic-based biotherapeutics aimed at establishing, restoring, and maintaining a healthy human microbiome. Incorporated in 2011, the company utilizes a discovery platform that addresses dysbiosis issues throughout the human life cycle and in production animals. Evolve Biosystems specializes in probiotic bacteria activated with specific prebiotic oligosaccharides and employs various delivery systems to support gut health, particularly in infants during their first six months of life. Their product offerings include consumer-directed solutions for home use as well as specialized products for neonatal intensive care units, addressing unmet clinical needs in both human and animal health.

Scripps Research, established in 1924, is a prominent, not-for-profit biomedical research institution with campuses in La Jolla, CA, and Jupiter, FL. Employing around 3,000 people, it's renowned for its contributions to science and health, including breakthroughs in cancer, rheumatoid arthritis, and hemophilia treatments. The institute, which ranks among the top ten for its graduate program in biology and chemistry, is led by distinguished scientists, including Nobel laureates. Its drug discovery and development division, Calibr, collaborates with scientists to expedite the delivery of innovative medicines to patients. Scripps Research is recognized as a leader in biomedical innovation, ranking No.1 by the Nature Index.

Novartis is a global healthcare company headquartered in Switzerland, dedicated to addressing evolving patient needs worldwide. It operates through several divisions: Novartis Pharmaceuticals for innovative medicines, Sandoz for generics and biosimilars, and Alcon for eye care devices. The company focuses on key therapeutic areas such as oncology, rare diseases, neuroscience, immunology, respiratory, and cardio-metabolic diseases. Novartis also invests in early-stage life sciences and biotechnology companies through its venture capital arm, Novartis Venture Fund, seeking innovative therapeutics, medical devices, diagnostics, and drug delivery systems. Additionally, Novartis Animal Health develops products for pets, farm animals, and farmed fish, contributing to animal health and welfare. The company's research and development efforts are supported by the Genomics Institute of the Novartis Research Foundation, which bridges basic science and preclinical drug discovery.

Immunethep is a biotechnology company specializing in the development of immunotherapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company has leveraged its proprietary technology to uncover a novel mechanism by which various pathogenic bacteria inhibit the host immune response. This discovery enables Immunethep to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, the company is developing neonatal vaccines aimed at protecting infants from bacterial infections while still in the womb, allowing for the enhancement of immunity and prevention of multi-bacterial infections. Through its innovative approach, Immunethep addresses significant unmet medical needs in the realm of infectious diseases.

Ventria Bioscience, Inc. is a biotechnology company based in Fort Collins, Colorado, specializing in the development, manufacturing, and marketing of health and nutrition products. Founded in 1993, the company focuses on human nutrition and therapeutics, offering a product portfolio that includes lactoferrin and lysozyme glycoproteins, which are beneficial for gastrointestinal health, dietary management of acute diarrhea, and treatment of various infections and inflammations. Ventria also provides OptiVERO, a specialized cell culture media for vaccine manufacturing, and supports researchers through its BioShare program, which grants access to recombinant proteins and peptides for research purposes. The company utilizes its patented ExpressTec technology, a plant-based recombinant protein manufacturing system that significantly increases protein yield, to drive innovation in biotherapeutics, novel vaccines, and other applications.

PnuVax Incorporated is dedicated to the production of high quality biopharmaceuticals for the promotion of public health worldwide. Their team has over 30 years of experience in the pharmaceutical industry, from research to full scale production.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with an additional office in Conshohocken. Founded in 1999, the company focuses on the discovery and development of innovative T cell receptor-based therapeutics aimed at addressing significant unmet medical needs in cancer, viral diseases, and autoimmune diseases. Immunocore specializes in engineering T cell receptors (TCRs) and linking them to antibody fragments, which has led to the development of its lead product candidate, IMCgp100, currently undergoing clinical trials for metastatic melanoma. The company's proprietary TCR technology platform is validated and designed for efficient manufacturing, supporting both clinical and commercial supply. Immunocore was previously known as Avidex Limited before adopting its current name in 2008.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company specializes in the development and commercialization of silk biomaterial technologies, particularly the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapeutics. This innovative sustained release patch technology enhances vaccine administration by simulating a natural infection, promoting a robust and prolonged immune response, thereby improving vaccine effectiveness. Additionally, Vaxess’s MATRIX formulation and drying platform creates thermostable vaccines, therapeutics, and diagnostic products that do not require refrigeration, making them suitable for distribution in low-resource settings. Through these advanced solutions, Vaxess aims to improve patient outcomes in oncology care and infectious diseases while reducing treatment burdens for healthcare practitioners.

Danforth Technology Company (DTC) is a venture builder based in St. Louis, Missouri, and operates as a subsidiary of the Donald Danforth Plant Science Center. Its primary role is to facilitate the early-stage development of startup companies that leverage technologies developed by the Center's scientists. DTC focuses on moving scientific discoveries into the marketplace more efficiently by providing intellectual property development, licensing, and entrepreneurship support. The company also offers seed funding and early management assistance to promising startups, enhancing the potential for innovation in plant science and contributing to broader societal goals such as improving human health and environmental sustainability.

AbCellera is a biotechnology company specializing in antibody discovery and development. It uses an integrated platform combining proprietary hardware, software, tools, and advanced data science to efficiently identify and develop optimal antibodies for clinical use. The company partners with both emerging biotechs and established pharmaceutical companies, leveraging its expertise to accelerate the drug development process and improve patient outcomes.

Mologic Ltd. is a UK-based company established in 2003 that specializes in the development of diagnostic products for the research market. The company focuses on various areas including clinical research, diagnostic development, enzyme-free blood glucose monitoring, microbial physiology, peritoneal dialysis, and wound care research. Mologic offers a range of diagnostic tools such as lateral flow kits for measuring human Alpha-1 antitrypsin, desmosine ELISA kits for urinary assays, and fMLP assay kits designed for solid-phase competition assays. In addition to its product offerings, Mologic provides services in assay and reagent development, clinical evaluation studies, and the creation of high-performance antibodies for challenging targets. The company's mission is to enhance patient care and quality of life, contributing to significant advancements in healthcare and education.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on the agriculture industry through the development of biological products. Founded in 2012, AgBiome leverages its expertise in plant-associated microbes and modern genomics to create innovative solutions aimed at enhancing plant health, pest resistance, and crop yields. The company addresses critical agricultural challenges, including soil-borne diseases, insects, and nematodes, by offering fungicides and a platform that identifies and screens diverse microbial strains. AgBiome collaborates with prominent agricultural partners to accelerate discovery processes and broaden the reach of its sustainable products in global markets. With a dedicated team of over 85 employees and a state-of-the-art laboratory and greenhouse facility, AgBiome is committed to improving food production responsibly.

Batavia Biosciences specializes in expediting the transition of biopharmaceutical products from discovery to clinical trials. They offer a range of services including candidate selection, production of research materials, process development (upstream and downstream), assay development, product characterization, and clinical manufacturing. Their expertise spans viral and bacterial vaccines, recombinant proteins, antibodies, and gene therapy products. Batavia Biosciences employs unique technologies like STEP® protein expression technology and SCOUT® high throughput process technology to accelerate timelines and reduce costs for their clients.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company based in Hangzhou, China, that specializes in the development of antibody and recombinant protein biotherapeutics. Founded in 2016, the company focuses on leveraging its expertise in molecular design, process design, and drug product design to facilitate the development of biologics. By employing advanced protein, process, and manufacturing sciences, Hangzhou Just Biotherapeutics aims to overcome technical challenges associated with protein therapeutics, thereby accelerating development timelines and significantly lowering manufacturing costs. As a subsidiary of MabSpace Biosciences Co., Ltd., the company positions itself as a key player in the biopharmaceutical sector, dedicated to enhancing the efficiency of biomedical innovation.

Just Evotec Biologics, founded in 2014 and acquired by Evotec in 2019, specializes in the development of biotherapeutic technologies aimed at expanding global access to these treatments. The company leverages its expertise in antibody discovery, molecular design, and manufacturing processes to create innovative solutions that accelerate the development of biotherapeutics while significantly lowering manufacturing costs. Utilizing machine learning-driven technologies, Just Evotec Biologics provides clients with integrated designs that streamline the entire process from development to production, ensuring efficient and effective delivery of biologic therapies.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.